Aurinia Historical Financial Ratios
| AUPH Stock | USD 8.98 0.03 0.34% |
Aurinia Pharmaceuticals is presently reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 3.58 or Days Sales Outstanding of 69.52 will help investors to properly organize and evaluate Aurinia Pharmaceuticals financial condition quickly.
Aurinia |
About Aurinia Financial Ratios Analysis
Aurinia PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aurinia Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aurinia financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aurinia Pharmaceuticals history.
Aurinia Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Aurinia Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aurinia Pharmaceuticals sales, a figure that is much harder to manipulate than other Aurinia Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from Aurinia Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Days Of Inventory On Hand is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Current Ratio is estimated to increase to 6.98, while Price To Sales Ratio is projected to decrease to 6.97.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.28 | 1.83 | 3.27 | 2.2 | Days Of Inventory On Hand | 6.5K | 1.6K | 1.0K | 1.1K |
Aurinia Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Aurinia Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aurinia Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.9K | 32.69 | 64.88 | 4.57 | 7.34 | 6.97 | |
| Ptb Ratio | 6.89 | 4.02 | 6.18 | 1.51 | 3.41 | 3.58 | |
| Days Sales Outstanding | 171.07 | 422.39 | 123.37 | 36.72 | 50.1 | 69.52 | |
| Book Value Per Share | 2.94 | 3.44 | 3.7 | 2.86 | 2.64 | 2.51 | |
| Free Cash Flow Yield | (0.0337) | (0.0471) | (0.0538) | (0.13) | (0.0265) | (0.0279) | |
| Operating Cash Flow Per Share | (0.68) | (0.59) | (1.22) | (0.56) | (0.23) | (0.25) | |
| Stock Based Compensation To Revenue | 14.82 | 23.31 | 0.35 | 0.69 | 0.26 | 0.25 | |
| Capex To Depreciation | 0.0672 | 5.36 | 0.54 | 0.11 | 0.0616 | 0.0586 | |
| Pb Ratio | 6.89 | 4.02 | 6.18 | 1.51 | 3.41 | 3.58 | |
| Ev To Sales | 5.0K | 27.43 | 59.98 | 3.93 | 7.61 | 7.23 | |
| Free Cash Flow Per Share | (0.68) | (0.65) | (1.23) | (0.56) | (0.24) | (0.25) | |
| Roic | (0.5) | (0.3) | (0.26) | (0.28) | (0.23) | (0.22) | |
| Net Income Per Share | (0.92) | (0.76) | (1.33) | (0.87) | (1.4) | (0.54) | |
| Payables Turnover | 12.73 | 19.1 | 0.28 | 1.83 | 3.27 | 2.2 | |
| Sales General And Administrative To Revenue | 69.67 | 1.92 | 3.76 | 1.47 | 1.11 | 1.06 | |
| Research And Ddevelopement To Revenue | 166.25 | 1.0 | 1.12 | 0.34 | 0.28 | 0.27 | |
| Capex To Revenue | 0.33 | 0.15 | 0.0329 | 0.002179 | 0.004091 | 0.003886 | |
| Cash Per Share | 3.29 | 3.36 | 3.6 | 2.74 | 2.45 | 2.32 | |
| Pocfratio | (29.7) | (23.45) | (18.76) | (7.71) | (38.48) | (36.56) | |
| Interest Coverage | (67.04) | (25.14) | (2.1K) | (21.78) | (33.04) | (34.69) | |
| Capex To Operating Cash Flow | (0.001639) | (0.11) | (0.009519) | (0.003672) | (0.0215) | (0.0225) | |
| Pfcf Ratio | (29.65) | (21.22) | (18.59) | (7.68) | (37.67) | (35.79) | |
| Days Payables Outstanding | 28.67 | 19.11 | 1.3K | 198.93 | 111.63 | 106.05 | |
| Income Quality | 0.51 | 0.68 | 0.87 | 0.74 | 0.43 | 0.41 | |
| Roe | (0.57) | (0.45) | (0.25) | (0.27) | (0.21) | (0.22) | |
| Ev To Operating Cash Flow | (24.88) | (19.68) | (17.35) | (6.63) | (39.94) | (37.94) | |
| Pe Ratio | (15.22) | (15.96) | (16.35) | (5.67) | (16.5) | (15.68) | |
| Return On Tangible Assets | (0.48) | (0.39) | (0.23) | (0.34) | (0.14) | (0.15) | |
| Ev To Free Cash Flow | (24.84) | (17.8) | (17.18) | (6.6) | (39.1) | (37.15) | |
| Earnings Yield | (0.11) | (0.0657) | (0.0627) | (0.0612) | (0.0606) | (0.0636) | |
| Intangibles To Total Assets | 0.0344 | 0.0201 | 0.0155 | 0.0136 | 0.009081 | 0.008627 | |
| Net Debt To E B I T D A | 3.41 | 2.56 | 1.26 | 0.83 | (0.77) | (0.73) | |
| Current Ratio | 27.9 | 13.11 | 12.63 | 9.6 | 5.5 | 6.98 | |
| Tangible Book Value Per Share | 2.82 | 3.36 | 3.64 | 2.81 | 2.6 | 2.47 | |
| Receivables Turnover | 2.13 | 0.86 | 2.96 | 9.94 | 7.29 | 9.7 | |
| Graham Number | 9.38 | 8.19 | 10.8 | 7.0 | 5.69 | 5.4 |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.